Quick Answer
Calidi Biotherapeutics, Inc. reported Diluted EPS of $5.95 per share (loss) for fiscal year 2025.
Calidi Biotherapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.95 | +83.3% |
| 2024 | -$35.70 | -106.0% |
| 2023 | -$17.33 | -679.6% |
| 2022 | $2.99 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.21 | +71.5% | -11.1% |
| June 30, 2025 | -$1.99 | +88.1% | -1005.6% |
| March 31, 2025 | -$0.18 | +91.1% | +97.7% |
| September 30, 2024 | -$7.75 | -449.6% | +53.7% |
| June 30, 2024 | -$16.75 | -17.6% | -725.1% |
| March 31, 2024 | -$2.03 | -170.7% | -44.0% |
| September 30, 2023 | -$1.41 | -123.8% | +90.1% |
| June 30, 2023 | -$14.24 | — | -1798.7% |
- Calidi Biotherapeutics, Inc. showed an increase of +83.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Calidi Biotherapeutics, Inc.’s diluted eps has declined by 299.0% (from $2.99 per share to $5.95 per share (loss)).
- The most recent figure is from Calidi Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: